Ribozyme Pharmaceuticals is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Boulder
State: Colorado
Zip:
Country: United States
Ribozyme Pharmaceuticals is a biotechnology company. It develops therapeutics based on RNA interference (RNAi) technology. The company provides research, preclinical, and clinical development services with product candidates in various areas including age-related macular degeneration (AMD), chronic hepatitis, dermatology, asthma, Huntington’s disease (HD), oncology, and diabetes. It offers Sirna-027, which completed phase I clinical trial and is used for the treatment of AMD; Sirna-034, which is under preclinical stage and is used for the treatment of hepatitis C virus; and various drugs under preclinical stage of development for asthma, HD, chronic hepatitis, diabetes, and dermatology. The company has strategic alliances with Allergan, Inc., Eli Lilly and Company, Targeted Genetics, Protiva, Archemix Corporation, and GlaxoSmithKline. Ribozyme Pharmaceuticals was founded in 1992 and is headquartered in San Francisco, California. As of March 5, 2014, it operates as a subsidiary of Alnylam Pharmaceuticals.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/1999 | Series B | 1 | $12M |
Morgenthaler Ventures Morgenthaler Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|